Pessary Care: Follow up and Management of Complications

Total Page:16

File Type:pdf, Size:1020Kb

Pessary Care: Follow up and Management of Complications SERIES Pessary Care: Follow Up and Management of Complications Katharine O’Dell and Shanna Atnip ESSARIES P ven after a successful pes- sary fitting, a woman’s © 2012 Society of Urologic Nurses and Associates level of satisfaction and O’Dell, K., & Atnip, S. (2012). Pessary care: Follow up and management of com- duration of pessary use plications. Urologic Nursing, 32(3), 126-137, 145. Eare difficult to predict. In one qualitative study, successful pes- Successful use of vaginal support pessaries requires provider and patient under- ERIES ON sary use was described by partic- standing of expected symptom-relief, potential complications, self-care options, S and evaluation and treatment of pessary-related problems. This second article in ipants as a learning process, lead- a three-part series summarizes clinical recommendations and evidence related ing to increasing comfort and to pessary management. confidence (Storey, Ashton, Price, Irving, & Hemmens, 2009). Key Words: Pelvic organ prolapse, pessary, therapy, complications. PECIAL Women initially reported feel- S ings of isolation and embarrass- Objectives: ment about pessary use. How- 1. Describe complications that may arise in women who use pessaries. ever, through encouraging inter- actions with providers, most 2. Explain the course of pessary follow up, including instructions, intervals between office visits, and pessary surveillance. commonly the office nursing staff, positive attitudes toward 3. Discuss pessary management and prevention of pessary-related complica- wearing a pessary developed tions. during follow up, and visits became anticipated social out- Duration of Pessary Use ings for several users (Storey et The first article in this series al, 2009). (Atnip & O’Dell, 2012) discussed Because women use pessaries clinical issues related to initiating for different reasons (for example, support pessary use, including a to totally avoid or defer surgery), Katharine O’Dell, PhD, CNM, WHNP-BC, summary of evidence related to is an Assistant Professor of OB/GYN, the patient and pessary selection, and duration of pessary use can be Division of Pelvic Medicine and Re - the likelihood of symptom relief. expected to vary. Reported use constructive Surgery, UMass Memorial continuation rates range from Medical Center, Worcester, MA. This article summarizes evidence related to pessary use, follow up, 56% to 70% in up to three years Shanna Atnip, MSN, WHNP-BC, is a Nurse and complications; describes cur- of follow up (Clemons, Aguilar, Practitioner, the Division of Urogynecology rent recommendations for clini- Sokol, Jackson, & Myers, 2004; and Reconstructive Pelvic Surgery, Komesu et al., 2007). One long- Parkland Health & Hospital System, and the cal practice where data are not University of Texas Southwestern Medical available; and identifies potential term follow-up study concluded Center, Dallas TX. areas for future research. that women are more likely to Note: Objectives and CNE Evaluation Form appear on page 137. Urologic Nursing Editorial Board Statements of Disclosure Statement of Disclosure: The authors In accordance with ANCC-COA governing rules Urologic Nursing Editorial Board state- reported no actual or potential conflict of ments of disclosure are published with each CNE offering. The statements of disclosure for interest in relation to this continuing nursing this offering are published below. education activity. Susanne A. Quallich, ANP-BC, NP-C, CUNP, disclosed that she is on the Consultants’ This learning activity was partially funded Bureau for Coloplast. by an unrestricted educational grant from All other Urologic Nursing Editorial Board members reported no actual or potential CooperSurgical, Inc. conflict of interest in relation to this continuing nursing education activity. 126 UROLOGIC NURSING / May-June 2012 / Volume 32 Number 3 continue pessary use if they are moval, bowel perforation and Bump, & Addison, 2000; Gorti, over 65 years or have comorbidi- sepsis, and uremia, urosepsis, Hudelist, & Simons, 2009; Pott- ties that increase surgical risk and/or kidney damage due to Grinstein & Newcomer, 2001). (Clemons, Aguilar, Sokol et al., infection and/or obstruction The following sections discuss 2004). In a case series of women (Arias, Ridgeway, & Barber, 2008). common self-care and provider seeing a single provider in Although these cases repre- care options. Australia (n = 273), 60% contin- sent severe morbidity and occa- ued pessary use for four weeks, sional mortality, only 39 of these Initial Instructions while 14% were continuing major complications were re - New pessary users are gener- users over an average follow up ported during a period of more ally instructed to note improve- of seven years (range: 2 to 14 than 50 years. Most cases oc - ment in symptoms and report S years) (Sarma, Ying, & Moore, curred in women with neglected new problems, such as pain or PECIAL 2009). During their period of fol- or forgotten pessaries, though discomfort, genital bleeding, low up, 44% of initial pessary two cases of vesicovaginal fistula abnormal vaginal discharge, sex- users opted to return to no inter- occurred in older adult women ual problems, and problems with vention, and 30% proceeded to who were obtaining regular care. elimination of urine or stool S surgery. These findings confirm The first was discovered two (Atnip, 2009). Optimal intervals ERIES ON that some, though not all, women hours after initial insertion of a for self-care have not been deter- can expect to experience an Ring pessary, suggesting a possi- mined, and recommendations extended period of satisfactory ble pre-existing, unidentified vary. For example, one pessary pessary use. vaginal wall abnormality. The manufacturer’s packet instruc- second occurred in a woman tion states that in ideal circum- P using a Gehrung (arch) pessary stances, users should be taught to ESSARIES Potential Complications During over a 12-year period. During remove all styles of pessary Pessary Use that time, she reportedly per- nightly for cleaning and reinser- The importance of on-going, formed daily self-removal, clean- tion (CooperSurgical, 2008). regular re-evaluation, even for ing, and re-insertion, and attend- Optional daily removal and women who are comfortable and ed regular follow-up visits. The cleaning are encouraged during asymptomatic during pessary latter case reminds providers the use of some pessaries, and use, must be emphasized to all and pessary-users that occasion- referred to as mandatory during providers and users. Because al serious complications may use of latex inflatable and Cube there is no centralized reporting occur even with the most dili- pessaries, the latter without refer- option, true pessary complica- gent care. ence to the presence or absence tion incidence is not known. Finally, in a recent case of drainage holes. In the 14-year follow-up of report, an 82-year-old woman For the newer silicone inflat- Australian Ring pessary users, experienced vaginal evisceration able pessary, manufacturer rec- 56% reportedly had some type of during initial fitting, causing dis- ommendations suggest removal complication, including genital placement of the pessary into the for cleansing every day or two bleeding, involuntary pessary abdomen, with resultant emer- (Panpac Medical Corporation, expulsion, unusual vaginal dis- gency colpocleisis (Rubin, Jones, 2010). When pessaries are re- charge, pain, and constipation & Harmanli, 2010). While the moved, they can be washed with (Sarma et al., 2009). Un - scarcity of reports suggests an soap and water, rinsed thorough- fortunately, this study design overall low-risk of serious pes- ly, and re-inserted, or stored for does not help women compare sary complications, these publi- future use. While providers may risks of pessary use with risks of cations highlight the need for offer women optional teaching untreated prolapse. careful assessment prior to pes- related to self-removal and re- While mild and/or transient sary placement at each routine insertion, some may not be either symptoms appear to be fairly visit and whenever new symp- able or willing to perform self- common during pessary use, rare toms occur. care (Sarma et al., 2009). serious adverse effects can also In addition, women initiat- occur, particularly if pessary ing pessary use are likely to have Pessary Follow Up care is neglected. In a review of many questions related to how individual case studies pub- While it seems clear that reg- pessary use may affect their lished between 1950 and 2007, ular pessary follow up is impor- lifestyle and activities. Some serious adverse events related to tant, both appropriate intervals answers will require experience. pessary use included vesicovagi- for follow-up and interim self- For example, women who are of nal and rectovaginal fistulas, care recommendations continue reproductive age may need to impaction or entrapment of the to be largely based on expert experiment to identify their pref- pessary requiring surgical re - opinion (Cundiff, Weidner, Visco, erence for management of their UROLOGIC NURSING / May-June 2012 / Volume 32 Number 3 127 SERIES Table 1. urine or stool likely to be reasons Self-Care Options for Women Using Vaginal Support Pessaries for emergent care. Recommendations for appro- Removal Intervals Between Visits: priate routine intervals for follow • Regularly (nightly, weekly, monthly) and re-insert post-cleansing up of women reporting comfort- • Regularly removed and leave out overnight able, effective pessary use also
Recommended publications
  • OVESTIN PESSARY (0.5Mg)
    NEW ZEALAND DATA SHEET 1. OVESTIN PESSARY (0.5mg) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pessary contains 0.5 mg Estriol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Pessary 0.5 mg - white, torpedo formed pessary. One pessary (2.5 g weight) contains 0.5 mg oestriol. Length 26.5 mm; largest diameter 14 mm. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Atrophy of the lower urogenital tract related to oestrogen deficiency, notably • for the treatment of vaginal complaints such as dyspareunia, dryness and itching. • for the prevention of recurrent infections of the vagina and lower urinary tract. • in the management of micturition complaints (such as frequency and dysuria) and mild urinary incontinence. Pre- and postoperative therapy in postmenopausal women undergoing vaginal surgery. A diagnostic aid in case of a doubtful atrophic cervical smear. 4.2 Dose and method of administration Dosage OVESTIN is an oestrogen-only product that may be given to women with or without a uterus. Atrophy of the lower urogenital tract 1 pessary per day for the first weeks, followed by a gradual reduction, based on relief of symptoms, until a maintenance dosage (e.g. 1 pessary twice a week) is reached. Pre- and post-operative therapy in postmenopausal women undergoing vaginal surgery 1 pessary per day in the 2 weeks before surgery; 1 pessary twice a week in the 2 weeks after surgery. A diagnostic aid in case of a doubtful atrophic cervical smear 1 pessary on alternate days in the week before taking the next smear. Administration OVESTIN pessaries should be inserted intravaginally before retiring at night.
    [Show full text]
  • UK Clinical Guideline for Best Practice in the Use of Vaginal Pessaries for Pelvic Organ Prolapse
    UK Clinical Guideline for best practice in the use of vaginal pessaries for pelvic organ prolapse March 2021 Developed by members of the UK Clinical Guideline Group for the use of pessaries in vaginal prolapse representing: the United Kingdom Continence Society (UKCS); the Pelvic Obstetric and Gynaecological Physiotherapy (POGP); the British Society of Urogynaecology (BSUG); the Association for Continence Advice (ACA); the Scottish Pelvic Floor Network (SPFN); The Pelvic Floor Society (TPFS); the Royal College of Obstetricians and Gynaecologists (RCOG); the Royal College of Nursing (RCN); and pessary users. Funded by grants awarded by UKCS and the Chartered Society of Physiotherapy (CSP). This guideline was completed in December 2020, and following stakeholder review, has been given official endorsement and approval by: • British Association of Urological Nurses (BAUN) • International Urogynecological Association (IUGA) • Pelvic Obstetric and Gynaecological Physiotherapy (POGP) • Scottish Pelvic Floor Network (SPFN) • The Association of Continence Advice (ACA) • The British Society of Urogynaecology (BSUG) • The Pelvic Floor Society (TPFS) • The Royal College of Nursing (RCN) • The Royal College of Obstetricians and Gynaecologists (RCOG) • The United Kingdom Continence Society (UKCS) Review This guideline will be due for full review in 2024. All comments received on the POGP and UKCS websites or submitted here: [email protected] will be included in the review process. 2 Table of Contents Table of Contents ................................................................................................................................
    [Show full text]
  • Pessary for Management of Pelvic Organ Prolapse
    Pessary for management of Pelvic Organ Prolapse Cathy Davis Clinical Nurse Specialist Department of Urogynaecology King’s College Hospital, London Definition of Prolapse The descent of one or more of the anterior vaginal wall, posterior vaginal wall, uterus (cervix) or vaginal vault (cuff scar after hysterectomy). The presence of any such sign should be correlated with relevant POP symptoms. (Haylen et al 2016) Risk Factors • Increased intra-abdominal pressure • Chronic cough • Chronic constipation • Weight lifting • Presence of abdominal tumours - fibroids & ovarian cysts • High impact exercise • Age/ Menopause • Obesity Risk Factors contd.... • Smoking • Multiparity • Congenital weakness – rare; due to deficiency in collagen metabolism • Injury to pelvic floor muscles • Iatrogenic/ pelvic surgery - hysterectomy Symptoms of POP • May be asymptomatic – a small amount of prolapse can often be normal • Sensation of a lump or bulge " coming down" - most common • Backache • Heaviness • Dragging or discomfort inside the vagina – often worse on standing /sitting for prolonged periods • Seeing a lump or bulge Symptoms of POP contd.... • Bladder / Urinary symptoms -Frequency -Difficulty initiating voids, low-flow, incomplete bladder emptying -Leakage on certain movements or when lifting heavy objects -Recurrent urinary tract infections • Bowel symptoms -Constipation - Incomplete bowel emptying - May have to digitate to defecate/use aides • Symptoms related to Sex – uncomfortable, lack of sensation Diagnosis of Prolapse • Vaginal examination •
    [Show full text]
  • Combi Soft Gel Pessary & External Cream
    Combi Soft Gel Pessary Canesten & External Cream 500mg vaginal capsule & 2% w/w cream Clotrimazole Read all of this leaflet carefully because it contains important To treat internal thrush, your doctor may recommend that you use the information for you. pessary without the help of an applicator. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. HOW TO USE CANESTEN® COMBI • This medicine has been prescribed for you. Do not give it to anyone else 3. under any circumstances. The Soft Gel Pessary: • If you have any unusual effects after using this product, tell your doctor. Unless directed otherwise by your doctor, the Soft Gel Pessary should be inserted as high as possible into the vagina, preferably before going to sleep IN THIS LEAFLET at night for convenient and comfortable treatment. Wash your hands before removing the foil from the blister pack and again 1. What is Canesten Combi and what is it used for? afterwards when you have used the applicator. 2. Before you use Canesten Combi 3. How to use Canesten Combi 1. Remove the applicator from the packaging. Pull out the plunger A until it 4. Possible side effects stops. Remove the pessary from the foil blister pack and place firmly into the 5. How to store Canesten Combi applicator B. 6. Further information 1. WHAT IS CANESTEN® COMBI AND WHAT IS IT USED FOR? Canesten Combi Soft Gel Pessary & External Cream is a full course of treatment for vaginal thrush (candidiasis) because it treats both the internal cause and external symptoms.
    [Show full text]
  • Management of Uterine Prolapse: Is Hysterectomy Necessary?
    DOI: 10.1111/tog.12220 2016;18:17–23 Review The Obstetrician & Gynaecologist http://onlinetog.org Management of uterine prolapse: is hysterectomy necessary? a b b, Helen Jefferis MRCOG, Simon Robert Jackson MD FRCOG, Natalia Price MD MRCOG * aSubspeciality Trainee in Urogynaecology, Department of Urogynaecology, Women’s Centre, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK bConsultant Urogynaecologist, Department of Urogynaecology, Women’s Centre, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK *Correspondence: Natalia Price. Email: [email protected] Accepted on 1 June 2015 Key content Fertility preservation remains the one absolute indication for Management of uterine prolapse is currently heavily influenced by hysteropexy. Other potential advantages include stronger apical patient and surgeon preferences. support and reduced vaginal surgery. The traditional approach to uterine prolapse is vaginal Colpocleisis remains a valid option for a small cohort of patients. hysterectomy. However, this does not address the underlying Learning objectives deficiency in connective tissue pelvic floor support, and prolapse Options for the management of uterine prolapse. recurrence is common. How to help patients decide on a management plan. Uterine preservation surgery is increasing in popularity, both with surgeons and patients; there is currently little evidence to show Keywords: colpocleisis / hysteropexy / pelvic organ prolapse / superior outcome to hysterectomy. uterine preservation surgery / vaginal hysterectomy Please cite this paper as: Jefferis H, Jackson SR, Price N. Management of uterine prolapse: is hysterectomy necessary? The Obstetrician & Gynaecologist 2016;18: 17–23. DOI: 10.1111/tog.12220 Introduction significantly associated with regression of prolapse, leading the authors to suggest that the damage obesity causes to the When a woman presents with pelvic organ prolapse, the pelvic floor may be irreversible.
    [Show full text]
  • Female Pelvic Relaxation
    FEMALE PELVIC RELAXATION A Primer for Women with Pelvic Organ Prolapse Written by: ANDREW SIEGEL, M.D. An educational service provided by: BERGEN UROLOGICAL ASSOCIATES N.J. CENTER FOR PROSTATE CANCER & UROLOGY Andrew Siegel, M.D. • Martin Goldstein, M.D. Vincent Lanteri, M.D. • Michael Esposito, M.D. • Mutahar Ahmed, M.D. Gregory Lovallo, M.D. • Thomas Christiano, M.D. 255 Spring Valley Avenue Maywood, N.J. 07607 www.bergenurological.com www.roboticurology.com Table of Contents INTRODUCTION .................................................................1 WHY A UROLOGIST? ..........................................................2 PELVIC ANATOMY ..............................................................4 PROLAPSE URETHRA ....................................................................7 BLADDER .....................................................................7 RECTUM ......................................................................8 PERINEUM ..................................................................9 SMALL INTESTINE .....................................................9 VAGINAL VAULT .......................................................10 UTERUS .....................................................................11 EVALUATION OF PROLAPSE ............................................11 SURGICAL REPAIR OF PELVIC PROLAPSE .....................15 STRESS INCONTINENCE .........................................16 CYSTOCELE ..............................................................18 RECTOCELE/PERINEAL LAXITY .............................19
    [Show full text]
  • U.S. Medical Eligibility Criteria for Contraceptive Use, 2010
    Morbidity and Mortality Weekly Report www.cdc.gov/mmwr Early Release May 28, 2010 / Vol. 59 U.S. Medical Eligibility Criteria for Contraceptive Use, 2010 Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition department of health and human services Centers for Disease Control and Prevention Early Release CONTENTS The MMWR series of publications is published by the Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Introduction .............................................................................. 1 Disease Control and Prevention (CDC), U.S. Department of Health Methods ................................................................................... 2 and Human Services, Atlanta, GA 30333. How to Use This Document ......................................................... 3 Suggested Citation: Centers for Disease Control and Prevention. [Title]. MMWR Early Release 2010;59[Date]:[inclusive page numbers]. Using the Categories in Practice ............................................... 3 Recommendations for Use of Contraceptive Methods ................. 4 Centers for Disease Control and Prevention Contraceptive Method Choice .................................................. 4 Thomas R. Frieden, MD, MPH Director Contraceptive Method Effectiveness .......................................... 4 Peter A. Briss, MD, MPH Unintended Pregnancy and Increased Health Risk ..................... 4 Acting Associate Director for Science Keeping Guidance Up to Date ...................................................
    [Show full text]
  • Pessary Information
    est Ridge obstetrics & gynecology, LLP 3101 West Ridge Road, Rochester, NY 14626 1682 Empire Boulevard, Webster, NY 14580 www.wrog.org Tel. (585) 225‐1580 Fax (585) 225‐2040 Tel. (585) 671‐6790 Fax (585) 671‐1931 USE OF THE PESSARY The pessary is one of the oldest medical devices available. Pessaries remain a useful device for the nonsurgical treatment of a number of gynecologic conditions including pelvic prolapse and stress urinary incontinence. Pelvic Support Defects The pelvic organs including the bladder, uterus, and rectum are held in place by several layers of muscles and strong tissues. Weaknesses in this tissue can lead to pelvic support defects, or prolapse. Multiple vaginal deliveries can weaken the tissues of the pelvic floor. Weakness of the pelvic floor is also more likely in women who have had a hysterectomy or other pelvic surgery, or in women who have conditions that involve repetitive bearing down, such as chronic constipation, chronic coughing or repetitive heavy lifting. Although surgical repair of certain pelvic support defects offers a more permanent solution, some patients may elect to use a pessary as a very reasonable treatment option. Classification of Uterine Prolapse: Uterine prolapse is classified by degree. In first‐degree uterine prolapse, the cervix drops to just above the opening of the vagina. In third‐degree prolapse, or procidentia, the entire uterus is outside of the vaginal opening. Uterine prolapse can be associated with incontinence. Types of Vaginal Prolapse: . Cystocele ‐ refers to the bladder falling down . Rectocele ‐ refers to the rectum falling down . Enterocele ‐ refers to the small intestines falling down .
    [Show full text]
  • Pelvic Organ Prolapse
    Quality ID #429: Pelvic Organ Prolapse: Preoperative Screening for Uterine Malignancy – National Quality Strategy Domain: Patient Safety – Meaningful Measure Area: Preventable Healthcare Harm 2019 COLLECTION TYPE: MEDICARE PART B CLAIMS MEASURE TYPE: Process – High Priority DESCRIPTION: Percentage of patients who are screened for uterine malignancy prior to vaginal closure or obliterative surgery for pelvic organ prolapse INSTRUCTIONS: This measure is to be submitted each time a prolapse organ repair surgery is performed during the performance period. There is no diagnosis associated with this measure. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding. Measure Submission Type: Measure data may be submitted by individual MIPS eligible clinicians using Medicare Part B claims. The listed denominator criteria are used to identify the intended patient population. The numerator quality-data codes included in this specification are used to submit the quality actions allowed by the measure on the claim form(s). All measure- specific coding should be submitted on the claim(s) representing the denominator eligible encounter and selected numerator option. DENOMINATOR: All patients undergoing surgery for pelvic organ prolapse involving vaginal closure/obliterative procedure Denominator Criteria (Eligible Cases): All patients, regardless of age AND Patient procedure during
    [Show full text]
  • Obstetrics and Gyneclogy
    3/28/2016 Obstetrics and Gynecology Presented by: Peggy Stilley, CPC, CPC-I, CPMA, CPB, COBGC Objectives • Procedures • Pregnancy • Payments • Patient Relationships 1 3/28/2016 Female Genital Anatomy Terminology and Abbreviations • Endometriosis • Neoplasm • BUS • TAH/BSO • G3P2 2 3/28/2016 Procedures • Hysterectomy • Prolapse repairs • IUDs • Colposcopy Hysterectomy • Approach • Open • Vaginal • Total Laparoscopic • Laparoscopic assisted • Extent • Total • Subtotal • Supracervical • Diagnosis 3 3/28/2016 CPT Codes • Abdominal 58150 – • With or without removal tubes/ovaries 58240 • Some additional services • Vaginal 58260-58270 • Size of uterus < 250 grams, > 250 grams 58275-58294 • Additional services CPT Codes • LAVH 58541-58544 • Detach uterus , cervix, and structures through the scope 58548-58554 • Uterus removed thru the vagina • TLH • Detach structures laparoscopically entire 58570- 58573 uterus, cervix, bodies • Removed thru the vagina or abdomen • LSH • Detaching structures through the scope, 58541 – 58544 leaving the cervix • Morcellating – removing abdominally 4 3/28/2016 Hysterectomy Additional procedures performed • Tubes & Ovaries removed • Enterocele repair • Repairs for incontinence • Marshall-Marchetti-Krantz • Colporrhaphy • Colpo-urethropexy • Urethral Sling • TVT, TOT 5 3/28/2016 Procedures • 57288 Sling • 57240 Anterior Repair • 57250 Posterior Repair • +57267 Add on code for mesh/graft • 57260 Combo of A&P • 57425 Laparoscopic Colpopexy • 57280 Colpopexy, Abdominal approach • 57282 Colpopexy, vaginal approach Example 1 PREOPERATIVE DIAGNOSES: 1. Menorrhagia unresponsive to medical treatment with resulting chronic blood loss anemia POSTOPERATIVE DIAGNOSES: 1. Menorrhagia 2. Blood loss anemia TITLE OF SURGERY: Total abdominal hysterectomy ANESTHESIA: GENERAL ENDOTRACHEAL ANESTHESIA. INDICATIONS: The patient is a lovely 52-year-old female who presented with menorrhagia that is non- responsive to medical treatment.
    [Show full text]
  • Histopathology Findings of the Pelvic Organ Prolapse
    Review Histopathology fndings of the pelvic organ prolapse FERNANDA M.A. CORPAS1, ANDRES ILLARRAMENDI2, FERNANDA NOZAR3, BENEDICTA CASERTA4 1 Asistente Clínica Ginecotocológica A CHPR, 2 Residente de Ginecología, Clínica Ginecotocológica A CHPR, 3 Profesora Adjunta Clínica Ginecotocológica A CHPR, 4 Jefa del servicio de Anatomía Patológica del CHPR, Presidenta de la Sociedad de Anatomía Patológica del Uruguay, Centro Hospitalario Pereira Rossell (Chpr), Montevideo, Uruguay Abstract: Pelvic organ prolapse is a benign condition, which is the result of a weakening of the different components that provide suspension to the pelvic foor. Surgical treatment, traditionally involve a vaginal hysterectomy, although over the last few decades the preservation of the uterus has become more popular. The objective of the paper is to analyze the characteristics of those patients diagnosed with pelvic organ prolapse, whose treatment involved a vaginal hysterectomy and its correlation to the histopathological characteristics. Retrospective, descriptive study. Data recovered from the medical history of patients that underwent surgical treatment for pelvic organ prolapse through vaginal hysterectomy, were analyzed in a 2 years period, in the CHPR, and compared to the pathology results of the uterus. At the level of the cervix, 58,2% presented changes related to the prolapse (acantosis, para and hyperqueratosis) and 43,6% chronic endocervicitis. Findings in the corpus of the uterus were 58,2% atrophy of the endometrium, 21% of endometrial polyps and 30.9% leiomiomas and 1 case of simple hyperplasia without cellular atypias. No malignant lesions were found. The pathology results of the uterus reveal the presence of anatomical changes related to the pelvic organ prolapse and in accordance to the age of the patient, as well as associated pathologies to a lesser extent.
    [Show full text]
  • Gynecological-DBQ
    INTERNAL VETERANS AFFAIRS USE GYNECOLOGICAL CONDITIONS DISABILITY BENEFITS QUESTIONNAIRE IMPORTANT - THE DEPARTMENT OF VETERANS AFFAIRS (VA) WILL NOT PAY OR REIMBURSE ANY EXPENSES OR COST INCURRED IN THE PROCESS OF COMPLETING AND/OR SUBMITTING THIS FORM. PLEASE READ THE PRIVACY ACT AND RESPONDENT BURDEN INFORMATION ON REVERSE BEFORE COMPLETING FORM. NAME OF PATIENT/VETERAN PATIENT/VETERAN'S SOCIAL SECURITY NUMBER NOTE TO PHYSICIAN - Your patient is applying to the U.S. Department of Veterans Affairs (VA) for disability benefits. VA will consider the information you provide on this questionnaire as part of their evaluation in processing the claim. VA reserves the right to confirm the authenticity of ALL DBQs completed by private health care providers. IS THIS DBQ BEING COMPLETED IN CONJUNCTION WITH A VA21-2507, C&P EXAMINATION REQUEST? YES NO If no, how was the examination completed (check all that apply)? In-person examination Records reviewed Other, please specify: Comments: ACCEPTABLE CLINICAL EVIDENCE (ACE) INDICATE METHOD USED TO OBTAIN MEDICAL INFORMATION TO COMPLETE THIS DOCUMENT: Review of available records (without in-person or video telehealth examination) using the Acceptable Clinical Evidence (ACE) process because the existing medical evidence provided sufficient information on which to prepare the DBQ and such an examination will likely provide no additional relevant evidence. Review of available records in conjunction with a telephone interview with the Veteran (without in-person or telehealth examination) using the ACE process because the existing medical evidence supplemented with a telephone interview provided sufficient information on which to prepare the DBQ and such an examination would likely provide no additional relevant evidence.
    [Show full text]